Aperio Group’s Unity Biotechnology UBX Stock Holding History

Aperio Group’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-527	Closed	-$50K	–	2738
2019 Q2	$50K	Buy	+527	New	+$44.8K	﹤0.01%	2532

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Aperio Group's UBX Position: Q3 2019 in Review

Aperio Group sold out of Unity Biotechnology (UBX) in Q3 2019, closing a stake of 527 shares — an estimated $50K sold.

Aperio Group first reported a position in UBX in Q2 2019 and held it in 1 quarter. The position peaked at $50K in Q2 2019. 63 funds tracked by Wall St. Rank hold UBX as of Q3 2019.

Aperio Group reported no remaining Unity Biotechnology position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 527 Unity Biotechnology shares in Q3 2019, an estimated $50K.
Aperio Group first reported a position in Unity Biotechnology in Q2 2019 and held it in 1 quarter.
Aperio Group's Unity Biotechnology position peaked at $50K in Q2 2019.
63 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.